List of Excipients in Branded Drug ACTHREL

« Back to Dashboard

ACTHREL Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

ACTHREL is corticorelin ovine triflutate, a synthetic corticotropin-releasing hormone used as an intravenous diagnostic agent in the evaluation of Cushing syndrome. Its commercial opportunity is limited by a narrow indication, low testing volume, and uncertain current availability. The strongest product strategy is a low-complexity sterile injectable with improved reconstitution, tighter peptide stability control, and reliable hospital supply rather than a broad reformulation program.

What is ACTHREL and how is it used?

ACTHREL is an intravenous formulation of corticorelin ovine triflutate, a 41-amino-acid peptide that stimulates pituitary ACTH release. The product is used as an adjunct to distinguish pituitary ACTH-dependent Cushing disease from ectopic ACTH secretion and other causes of hypercortisolism.[1]

Attribute	ACTHREL
Active ingredient	Corticorelin ovine triflutate
Drug class	Corticotropin-releasing hormone diagnostic peptide
Route	Intravenous
Dosage form	Lyophilized powder for reconstitution
Strength	100 mcg per vial
Primary use	Diagnostic evaluation of Cushing syndrome
Key excipient	Mannitol
Regulatory pathway	NDA drug product
Principal commercial constraint	Small, specialized diagnostic market

The product is administered in a controlled endocrine testing setting. Its value depends on assay timing, ACTH measurement, cortisol interpretation, and the ability of the test to affect surgical or medical management.

ACTHREL is not a chronic therapy. It does not generate recurring prescription volume comparable with glucocorticoids, incretin therapies, or replacement hormones.

What excipients are used in ACTHREL?

The marketed ACTHREL presentation is a sterile lyophilized peptide product containing mannitol as the principal bulking excipient. The vial is reconstituted before intravenous administration with Sterile Water for Injection according to the prescribing information.[1]

Why mannitol is technically relevant

Mannitol performs several functions in a peptide lyophilizate:

• It provides cake structure during freeze-drying.
• It supports acceptable vial appearance and handling.
• It can improve the physical stability of a low-dose peptide formulation.
• It avoids the reducing-sugar chemistry associated with excipients such as lactose or dextrose.

The active peptide is present at a low mass relative to the total cake. The formulation therefore depends on the bulking agent, buffer system, pH, residual moisture, and container closure for product quality.

Mannitol is not a complete stability strategy. Peptide degradation can involve aggregation, deamidation, oxidation, adsorption to surfaces, and loss of biological activity. A reformulator would need to control:

1. Reconstitution time.
2. Peptide recovery after dilution.
3. Visible and subvisible particles.
4. Potency after storage.
5. Freeze-drying cycle reproducibility.
6. Compatibility with the vial, stopper, and syringe.
7. In-use stability after reconstitution.

The critical quality attribute is biological activity measured through ACTH stimulation, not simply peptide content.

What excipient strategy is most commercially attractive?

The best near-term strategy is to preserve the established lyophilized vial while improving the user experience and manufacturing robustness. A full excipient redesign would add regulatory and technical risk without addressing the main commercial limitation, which is demand.

Strategy 1: Optimize the existing lyophilized formulation

A sponsor could retain mannitol and evaluate:

• Mannitol concentration and crystallinity.
• Low-level buffering agents.
• Tonicity adjustment.
• Residual moisture targets.
• Peptide adsorption control.
• Headspace oxygen management.
• Stopper compatibility.

This route is the most defensible for a 505(b)(2)-type development program because it maintains the known active ingredient, route, dose, and diagnostic use. The sponsor would still need comparative quality, stability, and clinical pharmacology data.

Strategy 2: Develop a ready-to-use liquid formulation

A liquid ACTHREL injection could eliminate reconstitution and reduce preparation errors. The technical challenge is long-term peptide stability at refrigerated or room temperature conditions.

A liquid formulation could use a low-ionic-strength buffer, tonicity agent, surfactant, and oxygen-control strategy. Each excipient would require evaluation for:

• Peptide aggregation.
• Chemical degradation.
• Intravenous tolerability.
• Container adsorption.
• Extractables and leachables.
• Compatibility with hospital dilution practices.

A ready-to-use product would have commercial value if it delivered a meaningful reduction in preparation time and wastage. The development burden would be materially higher than for a lyophilized reformulation.

Strategy 3: Use a dual-chamber presentation

A dual-chamber vial or syringe could separate the peptide cake from the diluent until administration. This would preserve a dry-state stability advantage while removing manual reconstitution.

The drawbacks are device cost, combination-product requirements, specialized manufacturing, and limited economic justification for a low-volume diagnostic. The presentation is more attractive for emergency or decentralized endocrine testing than for large academic centers with established pharmacy workflows.

Strategy 4: Develop a concentrated or microdose presentation

Dose flexibility has limited value because ACTHREL is used as a diagnostic bolus rather than a titrated therapy. A prefilled, single-use low-volume presentation could reduce measurement errors, but concentration changes would require bridging of pharmacodynamic results and administration procedures.

What patents protect ACTHREL?

ACTHREL’s principal commercial protection does not appear to depend on a durable, active patent estate. The active peptide, diagnostic concept, and lyophilized injectable format are mature technologies. The original composition, use, and formulation protection associated with the product would be expected to have largely expired or lost practical exclusivity.

Protection category	Commercial assessment
Active peptide composition	Mature and likely outside meaningful exclusivity
Diagnostic method	Potentially relevant only if claim scope remains enforceable
Lyophilized formulation	Possible historical protection; limited current moat
Container or device	Could protect a new presentation
Manufacturing process	May be maintained as know-how or trade secret
Current Orange Book leverage	Requires confirmation against the live FDA listing

No biosimilar pathway is relevant in the conventional sense. ACTHREL is a peptide drug rather than a therapeutic monoclonal antibody or other complex biologic marketed through the standard biologics framework.

A competitor could pursue an abbreviated or reliance-based pathway only if the reference product, FDA listing, and formulation comparability support that approach. For a peptide diagnostic, an ANDA may be difficult if the product cannot demonstrate pharmaceutical equivalence and bioequivalence in a conventional manner. A 505(b)(2) application would be a more practical route for a reformulated or differently presented product.

What is the Orange Book status of ACTHREL?

The Orange Book is the controlling source for current listed-drug status, patent certifications, and regulatory exclusivity information.[2] ACTHREL’s commercial relevance is reduced if the product is not actively marketed or if the reference listing is not available for a conventional generic pathway.

The key regulatory questions are:

• Whether ACTHREL remains listed as a current reference product.
• Whether the NDA has an active marketing status.
• Whether any patents remain listed.
• Whether a withdrawn product can support an abbreviated application.
• Whether FDA would require a new clinical pharmacology bridge.
• Whether the proposed formulation is eligible for 505(b)(2) reliance.

A sponsor should treat the Orange Book status as a gating issue. A technically superior formulation has limited value if the regulatory reference pathway is unavailable or requires a full NDA program.

When does ACTHREL lose exclusivity?

ACTHREL’s statutory exclusivity is not the principal barrier to entry. The product was approved in the United States in the late 1990s, placing any original new-drug exclusivity well in the past. Any remaining commercial protection would depend on listed patents, regulatory status, manufacturing capability, and clinical adoption rather than on unexpired basic exclusivity.

ACTHREL also does not have the typical long-tail patent profile seen in oncology, autoimmune, or specialty biologics. Its opportunity is therefore a supply and formulation play.

Are there Paragraph IV challenges to ACTHREL?

No material public Paragraph IV challenge is associated with ACTHREL in the principal litigation and generic-competition records commonly used for branded drugs. That absence is consistent with the product’s small market and limited expected generic revenue.

The lack of a Paragraph IV challenge does not mean entry is impossible. It indicates that the expected return from a conventional generic challenge may not justify development, litigation, and manufacturing costs.

A new entrant could instead avoid a direct patent dispute by pursuing:

• A 505(b)(2) reformulation.
• A different presentation.
• A new diagnostic protocol.
• A contract-manufactured hospital product.
• A product based on a related CRH or ACTH-stimulation approach.

What commercial opportunities exist for ACTHREL?

The opportunity is concentrated in specialty endocrine diagnostics, not mass-market prescribing.

Hospital and academic endocrine centers

The primary customer group is hospitals and academic centers that evaluate complex hypercortisolism. These institutions value:

• Reliable supply.
• Consistent assay timing.
• Low preparation burden.
• Stable reimbursement support.
• Clear interpretation protocols.
• Reduced pharmacy waste.

A manufacturer could compete through supply reliability and diagnostic workflow support rather than through price alone.

Contract manufacturing and private-label supply

A sterile injectable manufacturer with peptide lyophilization capability could pursue private-label or co-development arrangements with diagnostic companies, endocrine laboratories, and hospital purchasing organizations.

The manufacturing requirements create a moderate barrier:

• Peptide synthesis or qualified API sourcing.
• Sterile fill-finish.
• Validated lyophilization.
• Low-bioburden processing.
• Container closure integrity.
• Stability testing.
• Clinical assay support.

The market is too narrow to support inefficient manufacturing. A sponsor would need a small-batch facility or an established contract manufacturing organization.

International registration

Geographic expansion may offer more value than incremental U.S. formulation changes. Demand could exist in countries with specialized pituitary centers, but each market would require assessment of:

• Local availability of CRH stimulation testing.
• Reimbursement for endocrine diagnostics.
• Recognition of ACTHREL or corticorelin.
• Import and cold-chain requirements.
• Availability of validated ACTH assays.
• Competing diagnostic protocols.

The product may be commercially viable in selected markets even where U.S. volume is limited, provided regulatory registration and distribution costs remain controlled.

How does ACTHREL compare with competing diagnostic approaches?

Diagnostic approach	Role in Cushing evaluation	Commercial implication
ACTHREL stimulation	Supports differentiation of pituitary and ectopic ACTH sources	Specialized, low-volume injectable
High-dose dexamethasone suppression	Historical and still used in selected protocols	Oral, inexpensive, widely available
Inferior petrosal sinus sampling	Invasive localization test	Higher procedural cost, strong specialist value
CRH plus desmopressin protocols	Used in selected centers	Protocol-dependent and less standardized
Imaging and biochemical testing	Core diagnostic pathway	Competes for clinical decision-making budget

ACTHREL is most defensible where clinicians need a pharmacologic stimulation test and have access to timely ACTH assays. It is less attractive where imaging, inferior petrosal sinus sampling, or local protocols have replaced CRH stimulation.

What generic launch risks exist?

A generic or follow-on launch would face five primary risks:

1. Small addressable volume.
2. Limited reference-product availability.
3. Peptide-specific analytical and bioactivity requirements.
4. Low tolerance for assay variability in a diagnostic test.
5. Uncertain reimbursement and hospital formulary uptake.

A successful entrant would need to demonstrate that its product produces clinically interpretable ACTH responses comparable with the reference product. Chemical equivalence alone would not establish commercial credibility.

The most viable launch scenario is a single-vial sterile lyophilized product with the same active ingredient and dose, supported by a clear reconstitution protocol and dependable supply. A ready-to-use liquid is a secondary opportunity with higher technical risk.

How strong is the ACTHREL patent estate?

The patent estate is likely weak as a standalone barrier but can be reinforced through product-specific know-how. The most defensible assets for a new sponsor would be:

• A stable liquid formulation.
• A low-residual-moisture lyophilizate.
• A dual-chamber delivery system.
• A validated peptide manufacturing process.
• A proprietary assay or diagnostic workflow.
• Geographic registrations and hospital contracts.

Patent claims should focus on measurable formulation and stability parameters rather than broad claims to CRH stimulation. Process claims may have value where they produce a distinct impurity profile or stability advantage, but trade-secret protection may be more practical for manufacturing controls.

Key Takeaways

• ACTHREL is an intravenous corticorelin ovine triflutate diagnostic product for Cushing syndrome evaluation.
• Mannitol is the principal identified bulking excipient in the lyophilized formulation.
• The best first product strategy is an optimized lyophilized vial with improved reconstitution and stability.
• A ready-to-use liquid or dual-chamber presentation offers differentiation but carries higher technical and regulatory risk.
• The original exclusivity period is historical; current value depends on regulatory access, supply, formulation execution, and specialist adoption.
• The market is too narrow for a conventional high-volume generic strategy.
• A 505(b)(2)-type reformulation or specialty injectable supply strategy is more commercially credible than a standard Paragraph IV program.
• The strongest barriers are peptide manufacturing, sterile fill-finish, bioactivity comparability, and clinical workflow adoption.

FAQs

Is ACTHREL a biologic drug?

ACTHREL is a peptide drug administered as a sterile injectable. It is not a monoclonal antibody or conventional biosimilar product. Regulatory classification and abbreviated-pathway eligibility depend on the FDA reference listing and the proposed product’s comparability.

Can mannitol be replaced in an ACTHREL reformulation?

Yes, replacement is technically possible, but the sponsor would need to demonstrate equivalent stability, reconstitution, potency, impurity control, and intravenous tolerability. Mannitol is a logical benchmark because it is associated with the established lyophilized presentation.

Would a prefilled ACTHREL syringe have commercial value?

A prefilled syringe could reduce pharmacy preparation time and dosing error. Its value would depend on liquid stability, device compatibility, demand concentration, and whether the price premium exceeds combination-product and manufacturing costs.

Is ACTHREL interchangeable with desmopressin for Cushing testing?

No. Desmopressin-based protocols and corticorelin stimulation are different diagnostic approaches. Their clinical interpretation, patient selection, assay timing, and evidence base are not automatically interchangeable.

Does ACTHREL have biosimilar competition?

No conventional biosimilar competition is expected because ACTHREL is a peptide diagnostic product rather than a standard therapeutic biologic with a monoclonal-antibody-style biosimilar market.

References

1. U.S. Food and Drug Administration. (2012). ACTHREL (corticorelin ovine triflutate) injection, prescribing information. Ferring Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008). The diagnosis of Cushing’s syndrome: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 93(5), 1526-1540. https://doi.org/10.1210/jc.2008-0125